Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342427 · ClinicalTrials.gov registry record
Stomach Cancer Exosome-based Detection
A clinical trial of Gastric Cancer and Gastric Adenocarcinoma, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 809
- Enrollment target
- 3
- Study locations
NCT06342427 is a study of Gastric Cancer and Gastric Adenocarcinoma that has completed, run by City of Hope Medical Center. The registered enrollment target is 809 participants, above the 314-participant average among 153 other Gastric Cancer trials with a reported enrollment target (158% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT06342427, a study of Gastric Cancer and Gastric Adenocarcinoma, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 809 participants
- Enrollment target
- 3
- Study locations
Study Summary
Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST DESTINEX
Study Locations (3)
Other
- Nagoya University - Nagoya
- Mie University - Tsu
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2024-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06342427
The ClinicalTrials.gov registry entry for NCT06342427 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 809 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 314-participant average among 153 other Gastric Cancer trials with a reported enrollment target (158% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which DESTINEX is the first listed.
NCT06342427 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT06342427 about?
NCT06342427 is a clinical study titled "Stomach Cancer Exosome-based Detection". Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.
What is the current status of trial NCT06342427?
This trial is currently completed. The enrollment target is 809 participants. The study started on 2023-03-15. Estimated completion is 2024-06-15.
What conditions does trial NCT06342427 study?
This clinical trial studies the following conditions: Gastric Cancer, Gastric Adenocarcinoma, Gastric Neoplasm, Gastric Cancer Stage, Gastric Lesion.
What interventions are being tested in trial NCT06342427?
The interventions under investigation include: DESTINEX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06342427?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06342427 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.